Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23234544)

  • 1. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ; Cook SJ
    Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
    Sale MJ; Cook SJ
    Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
    Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
    Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
    Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
    Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction.
    Sale MJ; Balmanno K; Cook SJ
    Cancer Drug Resist; 2019; 2(2):365-380. PubMed ID: 35582726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
    Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
    Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
    Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
    Bid HK; Kibler A; Phelps DA; Manap S; Xiao L; Lin J; Capper D; Oswald D; Geier B; DeWire M; Smith PD; Kurmasheva RT; Mo X; Fernandez S; Houghton PJ
    Clin Cancer Res; 2013 Dec; 19(24):6716-29. PubMed ID: 24132923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
    Shi H; Moriceau G; Kong X; Lee MK; Lee H; Koya RC; Ng C; Chodon T; Scolyer RA; Dahlman KB; Sosman JA; Kefford RF; Long GV; Nelson SF; Ribas A; Lo RS
    Nat Commun; 2012 Mar; 3():724. PubMed ID: 22395615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
    Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
    Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
    Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
    Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
    Deuker MM; Marsh Durban V; Phillips WA; McMahon M
    Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.